• Kiniksa annual report for year ended Dec. 31, 2025 highlighted continued ARCALYST momentum in recurrent pericarditis, supported by broader prescribing, longer treatment duration, and deeper penetration across target patients.
• American College of Cardiology August 2025 guidance recommended IL-1 pathway inhibition after NSAIDs and colchicine for recurrent pericarditis, reinforcing shift toward earlier use versus corticosteroids.
• KPL-387 registrational Phase 2/3 program in recurrent pericarditis started recruiting in 2025, with Phase 2 data expected in second half of 2026; FDA granted orphan drug designation for pericarditis in October 2025, with launch targeted for 2028/2029.
• KPL-1161 remained in preclinical development, with Phase 1 first-in-human trial planned by end of 2026, positioning pipeline around longer-interval IL-1R1 inhibition options.
• Development of abiprubart in Sjögren’s disease was discontinued, with strategic alternatives under review for asset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiniksa Pharmaceuticals International plc published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.